OLUMIANT® Receives Health Canada Approval, Becoming the Second Approved Treatment for Severe Alopecia Areata in Canada
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
Navigate With Confidence
Navigate with Confidence: Mental Health Resources Resources Music & Wellbeing Handbook
LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved
Attack From Within: Living with Alopecia
We are pleased to share the “Attack from Within” alopecia patient video with you. This video follows Christal, Jen, Julia, and Sasha, as they share how alopecia affects their identity, their relationships, and their overall quality of life.
Alopecia areata: Navigating the emotional toll and financial burden of an unpredictable disease
Article from BC Medical Journal: Navigating the emotional toll and financial burden of an unpredictable disease